Founded in 1965, NMS Group is one of Europe's largest oncology R&D organizations, focusing on the discovery and early development of oncology drugs. Apart from its specialization in drug discovery, NMS is the only player that offers a turnkey through its integrated supply chain, from the pre-clinical phase of research to the First-In-Human clinical phase, concluding with the production and packaging phase of finished drugs. It has more than 400 employees, with over 100 of them being top scientists.

NMS is the best pharmaceutical R&D center in Italy. It has successfully developed eight original drugs including ADRIAMYCIN®, Ellence® and Aromasin®, and has extensive experience in target discovery and validation, kinase research and antibody-coupled drug platforms.

FunPlus is a Chinese video and mobile game development company founded in 2010 by CEO Andy Zhong (Chinese: 钟英武) and Yitao Guan, with headquarters in Beijing, China.

Specializing on social gaming development and distribution, FunPlus has also offices in San Francisco, U.S.A, and has developed and published several games on Facebook as well as on Apple, Google, and Amazon Store

Xiangjiang Technology is a cloud infrastructure service provider in China, headquartered in Zhenjiang New District. It has been deeply involved in the industry of communication infrastructure since its founding in 1999, forming a systematic and comprehensive data center investment and construction, planning and design, solutions, system integration, operation, and maintenance management of the entire life cycle service capabilities.

Xiangjiang Technology insists on innovation and technology as the driving force, based on the physical platform construction of cloud infrastructure, takes cloud infrastructure service provider as its responsibility, and conducts in-depth development and continuous refinement in the fields of the big data industry, digital city, intelligent manufacturing, etc. It is dedicated to enabling industry transformation and upgrading and continuously improving people's communication and lives.

Founded in 2015, Vertilite, as an innovative start-up company, develops and markets high power and high speed VCSEL (vertical-cavity surface-emitting laser) and module solutions.

Consisting of experienced scientists and engineers from the industry, Vertilite has successfully released products of high performance for diversified applications in 3D sensing, optical communications, industrial automation, biomedical applications, automotive applications, consumer electronics and LiDAR solutions.

TeamFounded in 2005, Zhejiang Century Huatong Group Co.,Ltd was originally focused on the automotive parts business. Before the company began its transformation into the internet gaming industry in 2014. In 2019, it completed its acquisition of Shengqu Games (formerly Shanda Games) for 29.8 billion yuan, becoming one of the top listed companies in the cultural media sector on the A-share market. Currently, Century Huatong encompasses three core businesses: internet gaming, automotive parts manufacturing, and AI cloud data, as well as multiple areas including brain science research, artificial intelligence, and investment. Tencent being a significant shareholder.

Heilongjiang LongMay Hospital currently has nearly 40 hospitals, including 3 top-three hospitals and more than 8,000 beds. It has developed into the most advanced medical complex in eastern Heilongjiang, the highest level of technology, the best medical services complex.

Jinma Pharmaceutical Group Co., Ltd. (000766.SZ) was established in 1990 with registered capital of 966 million yuan and total assets of 4.5 billion yuan. It is one of the earliest listed pharmaceutical companies in China. Since its listing, it has successively acquired wholly-owned shares of three pharmaceutical companies: Harbin Shengtai Biopharmaceuticals in Heilongjiang Province, Chengdu Yongkang Pharmaceutical in Sichuan Province, and Anyang Yubei Pharmaceutical in Henan Province. It also holds a wholly-owned controlling stake in Changchun Huayang Technology and holds equity stakes in three new drug research institutes: Beijing Minkang Baicao Technology and Shanghai Shijian Technology.

Jinma Pharmaceutical Group is a large-scale pharmaceutical company with Traditional Chinese Medicine as its leading focus, chemical drugs and biopharmaceuticals as its two wings, and innovative drugs at its core. It integrates modern drug research and development, production, and sales, and manages the entire industry chain.

Since Chairman Zhang Yufu took over, the company has adhered to the philosophy of "inheriting tradition while maintaining integrity and innovating." The company has focused on developing Traditional Chinese Medicine (TCM) and specialty APIs, while also actively developing new drug R&D and deepening its presence in chemical and biological medicines. With innovative drugs at its core, the company has established a framework for the integrated development of TCM, chemical, and biological medicines, with production and R&D progressing in tandem, striving to achieve the ambitious strategic goal of "Asianization of TCM and Internationalization of Chemical Medicine."

Under the leadership of Chairman Zhang Yufu, Tonghua Jinma Pharmaceutical Group is committed to brand building and in-depth development, continuing to expand and strengthen its core product lines further.

Founded in 2003, Nanjing Hicin Pharmaceutical Co.,Ltd (300584.SZ) is a High-Tech enterprise specialised in producing pharmaceutical preparations, manufacturing synthetic chemicals, conducting new drug R&D, as well as technical transferring.

It has established several modern workshops GMP-certified for sterile lyophilised powder, cephalosporin lyophilised powder and solid dosage forms (including tablets, capsules and granules) as well as synthetic Active Pharmaceutical Ingredients (APIs). The company produces 7 series of medicine: antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system and immuno-modulate agents, which are processed into several dosage forms.   

The company has built a strong R&D team led by PhD and Master’s degree holders, while maintaining extensive collaborations with leading domestic and international research institutions, including the prestigous China Pharmaceutical University. Creating a industry–academia–research innovation model. Through which Hicin has successfully registered and applied for a number of API and formulation products with strong market potential. It has established an innovation cycle of developing, reserving, and producing one generation after another. Thereby ensuring sustainable growth and continuous product innovation. 

Weimob is a WeChat third-party technology development and service provider. It provides customers with a full range of integrated solutions through WeChat platforms such as SaaS, precision marketing, social e-commerce, and financial technology. The company's current business mainly includes SaaS software and precision marketing. After four years of development, the company has 2,500 employees, more than 1,300 agents worldwide, and more than 2.2 million settled merchants. It has become the leading third-party service market in the WeChat ecosystem.
 
V-Capital set up an M&A fund with the major shareholder of the target, in order to assist the company's actual controllers in optimizing the shareholder structure and strengthening its control before the target’s Hong Kong securitization. While set adequate credit enhancement measures, we fully shared the growth of the target’s equity.

DK Electronic Materials (DKEM) founded in 2010 in Yixing, Wuxi, China. Rooted in the global energy transition and the national semiconductor strategy, DKEM adheres to a collaborative innovation approach driven by both technology and market orientation, and upholds the product philosophy of When Performance Matters.

With its expertise in metallization and interconnection technologies, DKEM focuses on two strategic fields — solar photovoltaics and semiconductor electronics — providing high-performance conductive paste products to empower a zero-carbon and better future.

Founded in 1991, Mindray is one of the leading global providers of medical devices and solutions. Headquartered in Shenzhen, China, Mindray possesses a sound global R&D, marketing and service network with subsidiaries and branch offices in 32 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 31 branch offices in China. To date, Mindray has nearly 7,600 employees.Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions. In China, Mindray’s products and solutions can be found in nearly 110,000 medical institutions and 99% of Class A tertiary hospitals.

In the process of dismantling the offshore structure of Mindray, V-Capital received the shares held by the foreign shareholders of Mindray by setting fund, and became the shareholder of Mindray before its domestic securitization. At present, the IPO of Mindray has entered the final stage.

Founded in 2009, iDreamSky is headquartered in Shenzhen. It is a leading Chinese digital entertainment platform, having developed top-quality games and the Play Together offline store to create a 24-hour online and offline entertainment community.

iDreamSky's games are a driving force behind Chinese games, and its products have stood the test of time. iDreamSky has expanded from publishing games to developing them as well. We have released Gardenscapes, Homescapes, Little Animal Star, Global Operations, Glory Stars, Subway Surfers, Temple Run 2, Monument Valley, and other great titles.

Weimob is a WeChat third-party technology development and service provider. It provides customers with a full range of integrated solutions through WeChat platforms such as SaaS, precision marketing, social e-commerce, and financial technology. The company's current business mainly includes SaaS software and precision marketing. After four years of development, the company has 2,500 employees, more than 1,300 agents worldwide, and more than 2.2 million settled merchants. It has become the leading third-party service market in the WeChat ecosystem.
 
V-Capital set up an M&A fund with the major shareholder of the target, in order to assist the company's actual controllers in optimizing the shareholder structure and strengthening its control before the target’s Hong Kong securitization. While set adequate credit enhancement measures, we fully shared the growth of the target’s equity.

MontageTechnology is a leading fabless semiconductor provider focusing on the data center and smart home entertainment markets. In the data center market, Montage delivers high-performance, secure and controllable CPU, memory module and memory interface solutions for new generation servers. In the smart home entertainment market, Montage provides highly integrated and customizable OTT/STB total solutions for home entertainment, and offers feature-rich, cost-effective consumer IoT solutions for wireless connectivity everywhere at home. Montage’s sophisticated technology platform allows it to deliver integrated solutions that meet the expanding needs of customers through continuous innovation, efficient design and rapid product development.

Founded in March 2010, Asieris Pharmaceuticals(688176.SH), is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. It strives to improve human health and help people live a more dignified life. It aims to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.

Asieris has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.

Founded in 2016, MGI is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

As of December 31, 2021, MGI has 2,050 employees, 35% of whom are R&D personnel. Founded in 2016, MGI operates in more than 80 countries and regions, serving more than 1,300 customers. It has established scientific research and production bases, global training and service network in many countries and regions around the world. MGI is one of the few companies in the world that can independently develop and mass-produce clinical high-throughput gene sequencers. Providing real-time, comprehensive, life-long solutions, its vision is to lead life science innovation.

PegBio is a biotechnology company focused on the development of new drugs for chronic diseases. The company focuses on independent research and development, focusing on large molecule innovative drug development, combined with core technologies such as long-acting drug release, to design, filter, and optimize candidate compounds for clinical needs with a huge market and unmet needs, resulting in preferred compounds with distinct advantages.

Cloudbreak Pharma is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.

Cloudbreak Pharma operates a capital-efficient business model based upon VIC + 505b(2). The company repurposes approved systemic drugs for ocular delivery to treat eye diseases and quickly advances drug candidates to complete proof-of-concept (POC) Phase II clinical trials and carry out Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC, and clinical development to efficiently maximize capital for drug development.

Shenzhen Lansus Technology Co., Ltd. was established in May 2015, with its headquarters in Shenzhen. It is a national high-tech enterprise and a "Little Giant" specialized and sophisticated new enterprise. The company specializes in the design and development of wireless RF chips, with products covering communication standards such as 5G/4G/3G/2G/Wi-Fi. Operating in a Fabless model, it primarily serves the mobile terminal market, including smartphones and tablets.

Shenzhen Photonx Technology Co.,Ltd. was established in 2018, with main members of the founding team from Peking University. They have been engaged in the development and research of new optoelectronic technologies for many years and have achieved fruitful research results. The company has multiple optoelectronic technology invention patents, and the Shenzhen headquarters, Beijing branch, and Zhangjiagang branch jointly form a complete system covering chip design & testing & encapsulation, laser device design & assembly and laser modules production.

 
The main products of Photonx include: single frequency narrow linewidth semiconductor lasers and modules, tunable narrow linewidth semiconductor lasers and modules, photonic crystal lasers, etc. Products are widely used in fields such as coherent optical communication, lidar, fiber optic sensing, laser ranging, and scientific research.

A leading technology company developing a new generation of DPUs and advanced silicon solutions for modern data centers. Founded by Dr. Sunny Siu and a core team each with over 20 years of experience in the semiconductor industry, the company has gathered a world-class silicon and software team formerly from Broadcom, Intel, Arm, HiSilicon (Huawei), and Alibaba.

Founded in 2018, Deptrum is a high-tech company focusing on the R&D of 3D vision technology and currently holds nearly 300 patents.

Deptrum pioneered the application of cutting-edge nano-optics technology in 3D vision, combined with AI algorithms to create a full-stack 3D vision solution with independent intellectual property rights. It has been applied in many fields, including payment, logistics, and intelligent robotics, due to its excellent mass production supply and practical implementation capability. Deptrum also provides high precision, cost-effective, and power-efficient 3D vision solutions, enabling large-scale adoptions in AI devices, AR/VR, AIoT, etc.

Founded in 1965, NMS Group is one of Europe's largest oncology R&D organizations, focusing on the discovery and early development of oncology drugs. Apart from its specialization in drug discovery, NMS is the only player that offers a turnkey through its integrated supply chain, from the pre-clinical phase of research to the First-In-Human clinical phase, concluding with the production and packaging phase of finished drugs. It has more than 400 employees, with over 100 of them being top scientists.

NMS is the best pharmaceutical R&D center in Italy. It has successfully developed eight original drugs including ADRIAMYCIN®, Ellence® and Aromasin®, and has extensive experience in target discovery and validation, kinase research and antibody-coupled drug platforms.

Founded in 1991, Mindray is one of the leading global providers of medical devices and solutions. Headquartered in Shenzhen, China, Mindray possesses a sound global R&D, marketing and service network with subsidiaries and branch offices in 32 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 31 branch offices in China. To date, Mindray has nearly 7,600 employees.Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions. In China, Mindray’s products and solutions can be found in nearly 110,000 medical institutions and 99% of Class A tertiary hospitals.

In the process of dismantling the offshore structure of Mindray, V-Capital received the shares held by the foreign shareholders of Mindray by setting fund, and became the shareholder of Mindray before its domestic securitization. At present, the IPO of Mindray has entered the final stage.

Cloudbreak Pharma is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.

Cloudbreak Pharma operates a capital-efficient business model based upon VIC + 505b(2). The company repurposes approved systemic drugs for ocular delivery to treat eye diseases and quickly advances drug candidates to complete proof-of-concept (POC) Phase II clinical trials and carry out Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC, and clinical development to efficiently maximize capital for drug development.

Founded in March 2010, Asieris Pharmaceuticals(688176.SH), is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. It strives to improve human health and help people live a more dignified life. It aims to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.

Asieris has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.

Shuyun is a leading provider of consumer growth solutions in China. Through an integrated solution that integrates software products and professional services, it supports brand retailers to establish a consumer operating system that drives consumer growth across the whole domain.

The company currently serves more than 3,000 domestic and international customers, covering well-known brands in various industries such as apparel, beauty, mother and child, food, 3C electronics, household, etc., and covering more than 300 million active consumers annually. Relying on rich industry experience and professional product services, Shuyun is becoming the first choice of brand retail enterprises as a full-domain consumer operation partner.

Vul.AI is a high-technology enterprise deeply engaged in the field of cyber security, specialising in vulnerability research, offensive and defensive operations, product development, and security services. The company is committed to integrating and innovating proactive defence and intelligence collaboration capabilities, building an attack surface management platform from an offensive–defensive perspective to deliver next-generation cyber security confrontation and defence solutions. It serves critical information infrastructure sectors such as finance, energy, education, and healthcare.

Vul.AI’s continuously evolving atomic security capability platform adheres to a data-driven and AI-led philosophy. By leveraging two core technologies — a knowledge-graph-based security risk library and a scenario-driven artificial intelligence engine — the platform flexibly combines modular security capabilities according to diverse business needs, enabling comprehensive protection within a single, unified system.

Lanxing Software is a leading provider of end-to-end digital decision-making solutions for supply chains in China. The company is committed to leveraging independent innovation and technology to drive social progress and to help enterprises reduce costs and improve efficiency through data-driven decision-making. Lanxing enables businesses to establish digital decision-making scenarios for supply chain planning and operations, empowering their digital transformation journeys.

Through its independently developed and patented supply chain decision-making platform SCATLAS, Lanxing delivers fast and precise answers to end-to-end supply chain decisions — from procurement, production, warehousing and logistics, to transportation and fulfilment. Combining extensive industry experience with cutting-edge implementation methodologies, Lanxing drives breakthrough improvements in enterprise supply chain management.

Upholding corporate values of “Self-motivation, Collaboration, Innovation, and Value,” Lanxing continually inspires new possibilities and has earned the trust of its clients as a leader in supply chain digital transformation. The company provides its SCATLAS platform and professional services to numerous renowned enterprises in China, including JD Logistics, Haier RRS, Mars Food, Tsingtao Brewery, Hisense, and Infinitus, ensuring that clients continuously derive sustainable business value.

Meichuang Technology, established in 2005, is a leading data security company in China, ranking among the top three in market share. With branches in 32 provinces and cities nationwide, the company offers four major services based on its innovative resilient data security framework: data security, operational security, data flow, and security operation services.

Meichuang serves over 16,000 users across various sectors, including government, finance, healthcare, energy, education, transportation, and logistics. As a key player in data security, Meichuang has participated in the formulation of more than 30 national industry standards, actively promoting industry-university-research cooperation and focusing on the fields of trusted computing and core protection. The company continuously safeguards the development of the digital economy with more comprehensive and innovative product solutions and services.

Founded in 2014, Definesys is a low-code PaaS platform provider specializing in enterprise software high productivity PaaS, dedicated to providing global enterprises with one-stop agile application and data integration digital solutions.

DeCod, the low-code platform, and DeFusion, the application integration platform, are Definesys' two core products, focusing on the dual capabilities of "application development" and "integration services" in the low-code domain, forming its first-mover advantage in the PaaS domain, meeting the needs of business applications and supporting unlimited personalized and differential customization capabilities, assisting enterprises in realizing digital transformation.

Gudou Resource Intelligent Optimization Collaboration Platform (RSO_PLAT) It is the core product of Gudou Technology. The platform abstracts the business scenarios of various optimization decisions in the production and operation process of the enterprise, forms a standard business model, adapts to the changes in the needs of the business scenarios, further builds advanced algorithm models, and applies various Intelligent algorithms realize optimization and solution, thereby helping enterprises realize intelligent optimization and business collaboration of various production resources, and scientifically improve operating efficiency. Including the full value chain of sales forecasting, supply chain planning, production job scheduling (APS), security inventory optimization and logistics distribution planning. The goal of Gudou Technology is to provide enterprises with in-depth insights into decision-making, support the optimization and collaboration of the upstream and downstream of the industrial chain, and promote the digital transformation of China's manufacturing industry.

Since its establishment in 2019, Gudou Technology has established cooperation with top universities and research institutions such as Tsinghua University, University of Science and Technology Beijing, and Tsinghua University Industrial Internet Industry Research Institute to jointly promote theoretical and technological development. Gudou's scientific and technological innovation strength has been obtained Multiple patents and autonomous intellectual property rights . After establishing global strategic cooperative relationships with leading companies such as Baidu, Huawei, Deloitte, Accenture, Alibaba, JD.com, and Baoxin, Gudou Technology will work with industry colleagues to create enterprise resource management solutions with intelligent optimization and collaboration capabilities to provide customers with Quick and effective decision support.

At present, Gudou Technology has successfully implemented systems for hundreds of companies in various industries such as new energy, FMCG, consumer electronics, medicine, steel, chemical industry, and food, and has provided services to CATL, Rongbai Technology, Xiaomi, By-Health, China Resources Sanjiu, Xianggang, Sinopec, etc., helping customers achieve major achievements in digital and intelligent transformation. In the future, Gudou Technology will continue to be committed to business innovation, industrial innovation, and ecological innovation, bringing a scientific, flexible, efficient, and implementable resource intelligent optimization collaboration platform to more enterprises, and promoting the tide of digital transformation and intelligent upgrading, fully implement let“ Maximize value for all resources ”corporate mission.

Beijing Donghua Botai Technology Co., Ltd. was established in November 2014 (formerly known as Beijing Zhongneng Botai Technology Co., Ltd.) with a registered capital of RMB 167.1875 million. Donghua Botai has long been deeply engaged in the fields of industrial internet, energy internet, and the internet of things (IoT). Leveraging a product system that captures industry expertise and empowers business scenarios, the company provides intelligent digital solutions for enterprises and institutions. Its solutions enhance their core competitiveness in achieving the “dual-carbon” goals and developing the “new-type power system”, thereby promoting the growth of new-quality productive forces.

Alauda is a global leader in cloud-native technology, providing cutting-edge solutions that empower enterprises to innovate, modernize, and achieve operational excellence. With a comprehensive suite of platforms, including Kubernetes-based container management, DevOps, AI, and microservices solutions, Alauda simplifies the complexities of digital transformation. Trusted by top organizations across industries, Alauda delivers hybrid and multi-cloud capabilities designed to enhance agility, streamline operations, and drive sustained business growth.

Sectrend is a pioneering force in AI-driven software supply chain governance. Its mission is enabled by an advanced tech stack, combining AI analytics, multi-dimensional vulnerability detection, and core engine R&D built upon DevSecOps "shift-left" principle.

Their solutions empower leaders in critical industries to master software supply chain security through a full-cycle "Discover-Analyze-Govern-Defend" approach. By combining global insights, sovereign technology, and AI, Sectrend is defining the future of the field—making it intelligent, automated, and inherently trustworthy.

Jiangsu SIGER Data Technology Co., Ltd. is an intelligent monitoring and control technology company specializing in the field of high-end manufacturing. It focuses on the three core links of tools, machine tools, and processes, and is committed to empowering the high-quality development of the manufacturing industry with data.

As a professional precision machining digital solution service provider, SIGER Data provides 7 major systems and 28 major module products, including unmanned tool monitoring, unmanned automatic measurement of tool compensation, production management system, CAPP production preparation system, quality traceability system, warehouse management system, and flexible line management system, providing customers in the precision machining industry with one-stop digital services.

In response to the call of Made in China 2025, SIGER Data was formally established in September 2016 with a capital injection of RMB 18.285947 million. It has gathered a number of elites with strong strength in computer technology, industrial data collection, big data analysis, industrial data application, industrial software development and other industries to form the SIGER R&D team, and tailor-made MES overall solutions for the precision machining industry for the domestic industrial market.

Founded in 2014, Camsense has been dedicated to the development of high-precision positioning vision sensors. The company specializes in providing core technology and product support for AI applications of all kinds.

As the first domestic enterprise with submillimeter positioning precision for monocular large space sensors, Camsense also represents the world's first company that develops, on its own, its algorithm chip in spatial positioning. The company has, up to now, obtained core algorithms and chips with completely independent intellectual property rights (70+ patent applications and 30+ authorizations).

GALAXIS TECHNOLOGY is an intelligent intralogistics robotics expert dedicated to redefining supply chain operations through cutting-edge embodied AI robotics technologies. We offer a full suite of robots centered on three core product lines: Multi-directional Shuttle Robots (MSR), Autonomous Mobile Robots (AMR), and Conveyor & Sorting Robots (CSR). These solutions deliver the essential intralogistics functions of storage/retrieval, sorting, and material handling, covering the entire spectrum of warehouse operations.

It ranks among the few companies globally with full-stack robotics capabilities and a comprehensive portfolio of self-developed robots that cover all core intralogistics functions across all height and payload specifications. Our core technological advantage stems from deep R&D in logistics-specific AI and control systems. Our unique closed-loop architecture enables seamless integration of perception, decision-making, execution, and feedback, delivering exceptional performance in complex logistics environments.